We’re On a Mission to Extend Longevity by TRANSFORMING How the World Treats Inflammation

Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling opioid use disorder, viral respiratory infections from coronaviruses such as COVID-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, and even the infamous hangover. Using our patented proprietary technology and the accelerated 505(b)2 pathway, we are on a mission to revolutionize the way we treat pain, and the way the business of pain relief treats humanity.

The Opioid CrisisTherapeutic Pipeline

Icon Repurposing

Repurposing

Two Small Molecules

By taking two already proven to be both effective and safe molecular agents and ingenuously combining them, Sen-Jam has discovered a simple yet powerful product that very well may change the way the world views pain relief. Our patent portfolio is rich with global relevancy and our clinical studies, both executed and planned exhibit a modern ingenuity not common to our peers.

Icon Reimagining

Reimagining

Partnerships

Our strategic partnerships run the full developmental spectrum and offer a refreshingly open model for partnerships to thrive and communities to benefit in multiple ways. From licensing to distribution and beyond, we embrace an entrepreneurial can-do spirit to transform the way healthcare connects commerce to caring.

Play Video

Sen-Jam’s Head of Clinical Development speaking to hundreds of innovators and health transformers at the StartUp Health Festival during JP Morgan’s Health Conference in San Francisco, January 2019

Over 470 Million
people worldwide

have been infected by COVID-19
(as of March 2022)

Icon Coronavirus

Over 6 Million
of them died
The Race to Find a
TREATMENT FOR CORONAVIRUS INFECTIONS

The world was stopped in its tracks by the incredible impact from the global pandemic. The COVID-19 ripple effects brings with it the third and greatest economic, financial and social shock of the 21st century, after 9/11 and the global financial crisis of 2008. And the controversy around vaccines and treatments creates even more chaos than calm. That said, there is a very promising, common sense approach to treating coronavirus infections to help mitigate disease progression that so often harrowingly leads to lung damage. The time is now for a smarter more modern approach to treating this pandemic. We believe and science supports this fact, that the true culprit is runaway inflammation. Let’s tackle this issue once and for all.

Icon Antivirals

The majority of treatments for COVID-19 today are anti-virals which come with

serious side effects
Icon Hospital Bed

The cost for one of the more prominent Big Pharma coronavirus treatments exceeds

$700 per dose

(SJP-002C hopes to be about a tenth of that cost)

Solving for the
ANCIENT AILMENT:
ALCOHOL HANGOVER

Since the discovery of alcohol thousands of years ago, drinkers have enjoyed consuming alcoholic beverages but also suffer from the next-day negative effects of alcohol intake. This so-called alcohol hangover is defined as the combination of negative mental and physical symptoms which can be experienced after a single episode of alcohol consumption, starting when blood alcohol concentration (BAC) approaches zero. Alcohol Hangover refers to the cluster of symptoms, including headache, nausea, thirst, and fatigue, occurring immediately after much or all of the alcohol has left the body following heavy drinking. The causes of hangover are unknown although hypotheses have been reviewed and for Sen-Jam, the most obvious and promising root source is the inflammation that occurs with ingestion of alcohol.

Icon Drinks
$1.5 Trillion
global alcohol beverage market

Icon 68 Percent

65% of people
who drink moderate levels of alcohol report
negative symptoms
the next day

Coffee Aspirin

75%
workers
claim they have been
hung over
at work
Icon 2of5
2 out of 5
employees claim they have
called in sick
due to hangover
Icon Down Arrow Green
68 Billion Lost

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Icon Pill

Putting an End to

The Opioid Crisis

Opioid Use Disorder is a problematic pattern of opioid use that leads to serious impairment or distress. It includes the use of prescription opoiods, heroin, or a combination of both. The intensity of withdrawal symptoms presents a significant barrier to abstinence and opioid dose reduction. Signs of chemical dependency are present within 5 days of opioid use.

100M
people suffer from chronic pain the U.S.
10-15M
people are prescribed opioids to manage pain
3-5M
people are currently diagnosed with Opioid Use Disorder*
Icon People 25
EVERY 25
overdoses results in
ONE DEATH
Overdoses occur
EVERY 17
SECONDS
and fatalities
EVERY 7
MINUTES
1.8M
overdoses
+
over 30K
deaths
annually
$700B
Estimated cost for substance abuse by the Council of Economic Advisors in 2017
Join us as we help put an end to the deadliest drug overdose crisis in American history
Icon Two Chevrons

A tragedy that has killed more people annually than the AIDS crisis, Vietnam and automobile accidents combined.

The agony of opioid withdrawal is far more debilitating than many realize.

It’s Time to Address This Head-on

Therapeutic Pipeline

Addressing Significant Unmet Needs with a Revolutionary Combination Anti-Inflammatory
Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3

Icon Rx  Prescription Strength Relief

SJP-002C SARS-CoV-2-Mild to Moderate infection - Oral
SJP-100 SARS-CoV-2-Severe infection - Injectable
SJP-005 Opioid Withdrawal - Oral
SJP-101 Opioid Withdrawal - Injectable
SJP-006 Opioid Dependence - Oral
SJP-007 Opioid Tolerance - Oral
SJP-009 Neonatal Abstinence Syndrome - Oral
SJP-004 Arthritis - Oral

Icon Otc  Over the Counter Relief

SJP-001 Alcohol Hangover Prevention - Oral
SJP-003 Adverse Effects from Vaccine Admin
SJP-500 Anti-Aging
SJP-002 Viral Respiratory Infection

Icon Rx  Prescription Strength Relief

SJP-002C SARS-CoV-2-Mild to Moderate infection - Oral
PHASE 2
SJP-100 SARS-CoV-2-Severe infection - Injectable
PHASE 2
SJP-005 Opioid Withdrawal - Oral
Preclinical
SJP-101 Opioid Withdrawal - Injectable
Preclinical
SJP-006 Opioid Dependence - Oral
Preclinical
SJP-007 Opioid Tolerance - Oral
Preclinical
SJP-004 Arthritis - Oral
Preclinical
SJP-009 Neonatal Abstinence Syndrome - Oral
Preclinical

Icon Otc  Over the Counter Relief

SJP-001 Alcohol Hangover Prevention - Oral
Phase 1
SJP-002 Viral Respiratory Infection - Oral
Preclinical
SJP-003 Adverse Effects from Vaccine Admin - Oral
Preclinical